Senate leaders slipped a last‑minute reprieve for hemp into a must‑pass spending bill, extending the November 12 ban on hemp THC products to December 11. The extension gives manufacturers and retailers extra time to adjust before the deadline.
The Continuing Appropriations and Extensions Act, 2027, cleared the Senate Appropriations Committee on August 2 and embeds Section 781, which pauses the synthetic cannabinoid ban while keeping natural‑derived hemp THC and full‑spectrum CBD on shelves. It applies only until December 11, after which the original timeline would resume.
Only products derived from naturally grown Cannabis sativa L. remain exempt; synthetic cannabinoids such as certain delta‑8 THC stay on the recriminalisation schedule for November 12. The distinction protects the broader hemp market from an abrupt shutdown.
The few‑week extension is meant to give industry lobbyists enough runway to secure a permanent fix in the next must‑pass funding bill, due on December 11. Stakeholders say the delay could prevent a market disruption and preserve jobs.
Industry Response and Legislative Moves
Representatives Andy Barr and Angie Craig introduced the Lawful Hemp Protection Act, which would repeal the ban and set up a regulatory framework. A Senate companion bill is expected from Tim Sheehy and Amy Klobuchar.
Representative James Comer is circulating a rival proposal that delays regulation while establishing a licensing system. The measure aims to balance consumer safety with market stability.
US Hemp Roundtable general counsel Jonathan Miller hailed the extension as a landmark victory. He said, “the reports of hemp’s death have been greatly exaggerated,” and urged the industry to push the language through both chambers before the December deadline.
President Trump has repeatedly urged Congress to protect full‑spectrum CBD while restricting products that pose health risks, and the Office of Management and Budget pressed Speaker Mike Johnson to ensure fair treatment of hemp items. The White House also launched a Medicare initiative covering up to $500 annually in hemp‑derived products for eligible patients.
The hemp beverage sector welcomed the reprieve. The Hemp Beverage Alliance said the Senate’s action supports responsible suppliers and urges the House to act quickly.
